Abstract
Introduction
Bacterial meningitis (BM) is an infectious disease associated with high lethality and morbidity, and survivors could have long-term sequelae. [1] [2] [3] [4] In Mexico, based on previous published data, BM due to Neisseria meningitidis is considered to be a rare condition, with a total number of cases in the whole country as low as two per year. 5 Streptococcus pneumoniae is a highly pathogenic bacteria, associated with sepsis, pneumonia (complicated/noncomplicated), otomastoiditis, and meningitis, among problems. 6, 7 Before implementation of the 13-valent pneumococcal conjugate vaccine (PCV13), S. pneumoniae was the leading cause of BM in many countries; [6] [7] [8] however, the use of this vaccine has drastically reduced BM by this pathogen. [9] [10] [11] Group B Streptococcus (GBS) is the leading cause of BM in young infants (<3 months of age) in many parts of the world, [12] [13] [14] [15] nevertheless, publications from Mexico City have shown that GBS is uncommon, with Enterobacteriaceae reported as the primary causes of BM in this age group. 16 In Mexico, vaccination against Haemophilus influenzae type b was introduced in 1999; PCV7 was introduced in May 2007; PCV13 in Tijuana, Mexico was introduced in May/June 2010; however, meningococcal vaccination, and GBS screening for pregnant women, are not part of Mexican health preventive policies.
The border between Tijuana, Mexico and San Diego, USA is the most populated on the planet, with significant bi-national health issues. [17] [18] [19] We researched to see whether N. meningitidis is an important cause of BM in children <16 years of age from our hospital, as well as to determine the effectiveness of PCV13 on pneumococcal BM, and the incidence of GBS as a cause of BM in young infants.
Materials and methods
From 1 October 2005 to 30 September 2018 (13 years), active/prospective surveillance for all children <16 years old admitted with suspected BM was performed at the Tijuana, Mexico, General Hospital.
Active surveillance is defined as 'syndromatic' and prospective, and was performed as follows:
All patients <16 years of age with clinical signs and symptoms suggestive of acute meningitis (<10 days of fever, with cephalalgia, meningeal signs, seizures, bulging of anterior fontanelle in young infants, altered state of consciousness), clinical febrile purpura, or sepsis, were included to confirm or rule out BM. Once the patient was admitted, both blood and cerebrospinal fluid (CSF) samples were taken for cytological and chemical analysis, 1 ml was immediately placed into enriched broth media (Bactec TM ) and followed by rapid (<3 minutes) incubation at 37°C with 5% of CO 2 . Final identification was performed using a MicroScan system (Vitek2 ® bioMerieux,San Diego, California, USA).
Confirmation of BM was done by conventional isolation from all positive broth media cultures, and, from 2013, polymerase chain reaction (PCR) was only used for all culture-negative 'granulocytic meningitis' (defined as a CSF with >5 cells/ mm 3 For the N. meningitidis serogroup PCR identification: PCR from the 1yS rDNA was sequenced with a ThermoSequenase radiolabeled terminator cycle sequencing kit (Amersham, Piscataway, New Jersey, USA ® ). Sequencing reaction contained 10 ng DNA amplified DT (Directed Termination)-PCR and purified with Microspins columns (Phamacia Biotech ® ) and 2.5 pmol Men1/Men2 primers. To assign a serogroup, a gene cassette required for the biosynthesis of the capsule of serogroups A, C, B, and W was used.
For S. pneumoniae molecular serotyping, a sequential multiplex PCR method approved by the journals.sagepub.com/home/tai 3 CDC (Center for Disease Control and Prevention, Atlanta, Georgia, USA) was performed. All serotype-specific primers were first tested with individual isolates of the targeted serotypes. To ensure that the primers would detect all strains within the given serotype, an additional 5 to 10 different clinical isolates within each targeted serotype were amplified with its corresponding primer sets.
Among survivors, all were discharged with a brain computed tomography scan and reviewed 3 months later to search for any neurological and other types of sequelae (these evaluations were done by the Departments of Pediatric Infectious Diseases and Pediatric Neurology). This last evaluation was merely a physical evaluation, with no other procedures performed.
Descriptive data were analyzed using Microsoft Excel ® .
PCV13 effectiveness, was performed by counting pneumococcal BM per month before and after its introduction (May 2012), followed by comparing the reduction in percentage (%) of that 'specific cases per month' number.
The hospital's standard of care was implemented for every admitted child, and the patient's (parent or tutor) consent form was the same as that used in the hospital. A datasheet containing information on every patient did not show names or other forms of identification to expose a patient's identity; this datasheet was only kept with the corresponding author of this study, and only privately showed when the hospital's institutional review board (IRB) required information. The hospital's IRB accepted the study based on these specifications.
Results
Demographic and clinical characteristics of all patients has partially been mentioned in the Materials and Methods section. Specific features for clinical presentations are described below, particularly for meningococcal and pneumococcal BM, and infants <3 months old. The general characteristics of the overall number of confirmed BM cases are shown in Table 1 .
The leading cause was N. meningitidis in 52 cases (60.5%), followed by S. pneumoniae in 16 cases (18.6%), GBS in 6 cases (7%), and 18 others (20.9%), shown in Figure 1 .
Meningococcal BM predominantly affected children <2 years old (n=22, 42.3%), with an age variation from 5 days to 15 years old. with the exception of a meningococcal outbreak during 2013 in which older children and adolescents were the predominant age group. 20 A total of 28 patients (53.8%) did not develop purpura. Serogroup distribution is shown in Figure 2 , with serogroup C the predominant type (61.5%), followed by Y and B. Mortality was 13 cases (25%), being higher in children who developed purpura, and, at admission, had thrombocytopenia or prolonged clotting times (46.15, 34.6, and 36.5%, respectively). Among survivors, 3 months after discharge, 13 patients (33%) had neurologic sequelae. The cases per year for both meningococcal and pneumococcal BM is shown in Figure 3 , clearly confirming a consistent, but variable, number of cases, particularly by meningococcal BM.
Pneumococcal BM was also more common in children <2 years of age (n=8, 50%), with an age variation from 1 month to 15 years old. All but one (a 1-month-old infant) had at least one dose of PCV13, and 13 (81.25%) had a complete PCV13 vaccination schedule according to their age. None developed purpura. Figure 4 ), and the disappearance of serotype 19A.
A total of 22 confirmed BM cases were found in young infants (<3 months old). The leading cause at this age group was GBS (n=6, 27.27%), followed by N. meningitidis (n=5, 22.72%, serogroups: 2-C, 2-B, and 1-Y), S. pneumoniae (n=4, 18.18%, serotypes 19A, 33C, 18B, and 12, one of each), Enterobacteriaceae (n=4, 18.18%), N. gonorrheae, 2 and L. monocytogenes 1 (see Figure 5 ). In this age group, death was mostly associated with newborns (<1 month old) with 6/16 deaths (37.5%).
Discussion
The data presented in this, long, active-surveillance-based study, confirm that, contrary to what has been reported in one publication in Mexico, 5 N. meningitidis is the leading cause of BM in Tijuana, Mexico, with serogroup C being the most prevalent. This study, along with an active-surveillance publication from nine hospitals in Mexico, and an outbreak of meningococcal BM caused by serogroup C, with clonal complex ST-11 (mortality >35%) in Tijuana during 2013, 20, 21 confirmed that meningococcal disease is endemic in the region, and universal vaccination should be seriously considered. Meningococcal vaccination with conjugate vaccines has shown effectiveness both in developed (USA, Canada) and developing countries in the Americas. [22] [23] [24] [25] PCV13 implementation has dramatically reduced pneumococcal meningitis in all countries where this vaccine is currently used. 26 In our region, we have published work confirming that PCV13 universal vaccination reduces overall invasive pneumococcal disease, 31 and in addition, with this present study, also the disappearance of serotype 19A, globally considered to be a very important replacement serotype following PCV7 implementation, as well as associated with high morbidity. 32, 33 In addition, in many countries, GBS in young infants is considered to be the leading cause of BM in this age group; [12] [13] [14] [15] however, published data from Mexico City emphasize that GBS is uncommon, with Enterobacteriaceae as predominant agents causing BM in young infants. 16 Our study shows the opposite, with GBS as the leading cause, with Enterobacteriaceae being present, but in smaller numbers.
The main limitation of our study is the lack of information based on active surveillance both in other hospitals at Tijuana, as in other cities in Mexico; however, our data are solid, and surveillance should never be interrupted.
The reason why our epidemiology of BM in our region differs from what has been published in Mexico City is unknown, but we speculate that this is caused by the distance between the two cities being long (more than 2000 kilometers). Tijuana shares, with San Diego, USA, the largest frontier in the planet, with potential similarities in epidemiology. [17] [18] [19] Furthermore, perhaps a problem exists with the epidemiological reporting system in Mexico, which is based on passive surveillance. 
Conclusion
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